ELV Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -4.28%, SMA50 -7.82%, SMA200 -4.9%). The stock’s 14-day RSI is 38.45 (weak momentum), while the ATR of 11.63 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -29.58% below its high and over 18.03% above its low. Average 10-day trading volume of 1.85 million shares is in line with the 3-month average of 1.71 million, indicating normal recent market interest.

Elevance Health Inc. last paid a dividend of 6.86 per share, this equals a trailing yield of roughly 1.15%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $925.16. This means the shares are trading below this model’s fair value.

Elevance Health Inc. (NYSE:ELV) closed at $417.89 USD, gaining $1.70 (0.41%) from the previous close of $416.19. The stock is currently within 5% of its 52-week high $273.71 and $427.19. With a market capitalization of about $90.75 billion, Elevance Health Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.68). Key stats such as the average daily volume over the past year has been around 1.75 million shares, volume is running light vs its 52-week average. Headquartered in Indianapolis, IN, Elevance Health Inc. operates in the Healthcare sector and the Medical - Healthcare Plans industry. Led by CEO Gail Koziara Boudreaux, the company employs approximately 104,200 people and listed since October 30, 2001. Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path.

Elevance Health Inc. has 225.18 million shares outstanding. The public float is 224.66 million shares, elevated short interest at 1.26% of float. This equals 2.84 million shares. The short ratio is 0.92 days. Institutional investors hold 93.41% of the float. Insiders own 0.17%. BOUDREAUX GAIL holds 144.85 thousand shares, Gallina John E has 54.32 thousand shares and MCCARTHY GLORIA M has 51.44 thousand shares. Over the past six months, insider transactions show net selling. They sold 5.27 thousand shares across 5 transactions.

Elevance Health Inc. generated EPS of $25.11 over the past year. Five-year average earnings growth is 6.99%. Wall Street analysts project EPS growth of 5.12% annually over the next five years. The latest quarter delivered EPS of $12.58. The next quarter is forecast at $10.58. Next year's EPS is expected at $12.19. Analyst sentiment is bullish. Analyst rating data shows there are 29 Strong Buy ratings, 19 Buy ratings, 11 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $498.00 to $297.00. The high target offers 19.17% upside. The low target suggests -28.93% downside. The mean target is $398.90. This offers -4.54% upside. Elevance Health Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 22, 2026, missed forecasts by 14.05%. The prior quarter beat by 7.42%. Over the last six quarters, Apple has recorded several small beats. These include 1.05% in January 23, 2025.

Elevance Health Inc. trades at a P/E ratio of 17.77, slightly below the S&P 500 average, with a price-to-sales ratio of 0.45 and a price-to-book ratio of 2.1 suggesting the stock is closer to book value. The P/FCF stands at 14.07, also above market averages.

Our AI price prediction model suggests that Elevance Health Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.04%, with price expected at $401.00 by July 16, 2026, within a range of $392.89 to $409.32 3-Month Outlook: Projected rise of 28.03%, reaching $535.04 by September 30, 2026, with a range of $491.78 to $575.64. 1-Year Outlook: Projected loss of -16.61%, with price at $348.47 by July 02, 2027, within a range of $330.39 to $369.35.

Elevance Health Inc. (NYSE:ELV) shares are flat 4.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Elevance Health Inc. trading at a premium to the broader market with a P/E of 17.77. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $462.67, suggesting 10.72% upside. Our AI forecast model points to short-term weakness (-4.04% over two weeks), a medium-term rise (28.03% over three months), and a longer-term loss (-16.61% over one year), with expected trading ranges indicating moderate volatility.